461 related articles for article (PubMed ID: 33689480)
1. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
5. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.
Zheng TJ; Parra-Izquierdo I; Reitsma SE; Heinrich MC; Larson MK; Shatzel JJ; Aslan JE; McCarty OJT
Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1231-C1250. PubMed ID: 35938677
[TBL] [Abstract][Full Text] [Related]
6. Differential Regulation of GPVI-Induced Btk and Syk Activation by PKC, PKA and PP2A in Human Platelets.
Zhang P; Solari FA; Heemskerk JWM; Kuijpers MJE; Sickmann A; Walter U; Jurk K
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175486
[TBL] [Abstract][Full Text] [Related]
7. Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets.
Tseng YL; Braun A; Chang JP; Chiang ML; Tseng CY; Chen W
Toxicol Appl Pharmacol; 2019 Feb; 364():106-113. PubMed ID: 30592962
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
9. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
[TBL] [Abstract][Full Text] [Related]
11. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.
Quek LS; Bolen J; Watson SP
Curr Biol; 1998 Oct; 8(20):1137-40. PubMed ID: 9778529
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein VI is not a Functional Platelet Receptor for Fibrin Formed in Plasma or Blood.
Zhang D; Ebrahim M; Adler K; Blanchet X; Jamasbi J; Megens RTA; Uhland K; Ungerer M; Münch G; Deckmyn H; Weber C; Elia N; Lorenz R; Siess W
Thromb Haemost; 2020 Jun; 120(6):977-993. PubMed ID: 32492725
[TBL] [Abstract][Full Text] [Related]
14. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
15. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
Series J; Ribes A; Garcia C; Souleyreau P; Bauters A; Morschhauser F; Jürgensmeier JM; Sié P; Ysebaert L; Payrastre B
J Thromb Haemost; 2020 Dec; 18(12):3336-3351. PubMed ID: 32926549
[TBL] [Abstract][Full Text] [Related]
16. Tec regulates platelet activation by GPVI in the absence of Btk.
Atkinson BT; Ellmeier W; Watson SP
Blood; 2003 Nov; 102(10):3592-9. PubMed ID: 12842985
[TBL] [Abstract][Full Text] [Related]
17. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of spleen tyrosine kinase at Y346 negatively regulates ITAM-mediated signaling and function in platelets.
Dangelmaier CA; Patchin M; Vajipayajula DN; Vari HR; Singh PK; Wright MN; Kostyak JC; Tsygankov AY; Kunapuli SP
J Biol Chem; 2023 Jul; 299(7):104865. PubMed ID: 37268160
[TBL] [Abstract][Full Text] [Related]
19. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
[TBL] [Abstract][Full Text] [Related]
20. Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling.
Irfan M; Jeong D; Saba E; Kwon HW; Shin JH; Jeon BR; Kim S; Kim SD; Lee DH; Nah SY; Rhee MH
Platelets; 2019; 30(5):589-598. PubMed ID: 29870296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
